Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Ondas Holdings And 2 Other Stocks Under $1 Insiders Are Buying

Published 20/11/2023, 13:45
© Reuters.  Ondas Holdings And 2 Other Stocks Under $1 Insiders Are Buying
VNRX
-

Benzinga - by Lisa Levin, Benzinga Editor.

The Dow Jones closed higher by around 2 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Innovative Food Holdings

  • The Trade: Innovative Food Holdings, Inc. (OTC: IVFH) 10% owner JCP Investment Holdings, LLC acquired a total of 255,000 shares an average price of $0.69. To acquire these shares, it cost around $175,850.
  • What’s Happening: The company posted GAAP net income of $0.134 million, or $0.003 per share for the third quarter.
  • What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.
Ondas Holdings
  • The Trade: Ondas Holdings Inc. (NASDAQ: ONDS) 10% owner Joseph V Popolo acquired a total of 342,880 shares at an average price of $0.71. To acquire these shares, it cost around $243,582.
  • What’s Happening: Ondas Holdings posted a narrower-than-expected quarterly loss.
  • What Ondas Holdings Does: Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India.
Check This Out: Agilent Likely To Report Lower Q4 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

VolitionRx

  • The Trade: VolitionRx Limited (NYSE: VNRX) CEO - Volition Veterinary Salvatore Thomas Butera acquired a total of 10,000 shares at an average price of $0.81. The insider spent around $8,100 to buy those shares.
  • What’s Happening: Cantor Fitzgerald recently maintained VolitionRX with an Overweight and raised the price target from $2.1 to $2.5.
  • What VolitionRx Does: VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.